Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma.

Winnie ChengVictoria KletasChristian KollmannsbergerMario de Lemos

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)

Based on retrospective, real-world data, alternative sunitinib dosing regimens appear to be viable options for patients with metastatic renal cell carcinoma.

Keyphrases

metastatic renal cell carcinoma
electronic health record
cross sectional
big data
machine learning
data analysis